Delivery Order SPE2DB20D1050-SPE2DB25FH85V
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $17,483.59 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-unit packaging) on July 14, 2025, with completion targeted for July 15, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion prime vendor agreement running through December 2026. The order will be fulfilled...
- The Defense Logistics Agency awarded a $32,318.92 firm fixed price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 1, 2025, with an ultimate completion date of August 4, 2025. This non-competitive delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The product will be performed at...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $25,083.77 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on June 13, 2025, with an ultimate completion date of June 16, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's larger...
- The Defense Logistics Agency (DLA) awarded a $21,909.46 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on August 20, 2025, with an ultimate completion date of August 21, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $80,832.18 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 45 mg tablets (28-count units) on July 22, 2025, with completion scheduled for July 23, 2025. This firm fixed-price, competitively awarded contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The contract involves no set-aside...
- The Defense Logistics Agency awarded a $42,773.33 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on July 23, 2025, with an ultimate completion date of July 24, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December 2026. The place of performance is listed...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,162.78 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count unit of use packaging) on June 16, 2025, with completion scheduled for June 17, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen Drug Corp's larger...
- The Defense Logistics Agency awarded a delivery order valued at $12,497.80 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 11, 2025, with an ultimate completion date of August 12, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $18,099.54 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count unit dose) on September 9, 2025, with completion scheduled for September 10, 2025. This competitive, non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger indefinite delivery contract (IDC) with DLA Troop Support Medical. The pharmaceutical product will be delivered to the...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,015.55 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count unit of use packaging) on August 22, 2025, with an ultimate completion date of August 25, 2025. This firm fixed-price, non-set-aside delivery order was competitively awarded and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a single transaction under AmerisourceBergen's larger indefinite...
- SPE2DB20D1050Indefinite Delivery Contract
- SPE2DB20D1050-SPE2DB25FH85VDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $49,967.02 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on August 26, 2025, with completion targeted for August 27, 2025. This competitively awarded, non-set-aside contract employs firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, fulfills extensive pharmaceutical supply requirements across the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems. The company's substantial IDC vehicle with DLA serves as a comprehensive global pharmaceutical support platform, enabling delivery of brand-name and generic medications, specialty pharmaceuticals, vaccines, and medical supplies across multiple therapeutic domains to support military healthcare programs worldwide. This delivery order for RINVOQ, a rheumatoid arthritis treatment, exemplifies the company's role as a primary pharmaceutical supplier within the federal medical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $50.0k | 8/26/25 |